The Cura Project Institute presents the companies that support the NGO in 2023.
In a world where the Journey against cancer it's a constant process, Cura Project Institute stands out as a important bridge between science and the patient, expanding awareness, education, and information about clinical research to combat cancer and encouraging fundraising for investment in academic studies.
In the year 2023, we look back with gratitude for the support that made, and will make possible, significant advances in cancer research and awareness.
The Cura Project Institute would not be able to fulfill its mission without the essential support of various institutions and individuals, and sees in each donation, the partnership and collaborative effort that have been fundamental to boosting our capacity to face cancer more effectively.
With this, we would like to express the importance of all the companies that supported the Cura Project in the last year: Prognostic Clinic, Cancer Institute of Brazil (ICB), Alta Saúde Home Care, ONE — Ocean Network, UMotivo Channel and The Magal Way. We also thank Breast International Group (BIG), LACOG, All Together Against Cancer and Brazilian Mastology Society for their institutional support.
We emphasize that each contribution is immeasurable, since the impact of research goes beyond what we can see translated into treatments. It is a support that leaves a mark on science and on the lives of everyone involved in this universe.
A Awareness-raising is a powerful tool in the fight against cancer. With the support of our partners, we were able to broaden the population's understanding of the importance of research and the challenges faced by those living with cancer. The dissemination of relevant information has been possible thanks to continuous collaboration with organizations committed to the cause.
Our big thanks to everyone! We will continue to fight, encourage research, and inspire hope until a cure is a reality for all.
Let's continue together to make 2024 even better!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
In an effort to understand the clinical research landscape in oncology in Brazil, the CURA Project Institute conducted a scientific study in partnership with LACOG - Latin American Cooperative Oncology Group, entitled “Current scenario and future perspectives of clinical research in Brazil: a national survey”.
Led by the lead author, Dr. Heloisa Resende, Oncologist and Researcher, member of the Latin American Cooperative Oncology Group (LACOG) and President of the Scientific Committee of the CURA Project Institute, in collaboration with a team of renowned researchers, the study aimed to evaluate the current behaviors and future trends of Brazilian oncologists in relation to clinical research in the care of their cancer patients.
The initial segment of the research focused on gathering information about demographic details, medical education, and prior participation in research. The subsequent part addressed the main barriers to involvement and participation in clinical trials in Brazil.
The findings of this study were published in the renowned journal eCancer Medical Science, showing the importance of research in the scientific community, and Dr. Heloisa Resende played a fundamental role in advancing this initiative. Check out the publication by accessing the link.
A notable achievement was the acceptance of this research for publication at ASCO 2023, the annual congress of the American Society of Clinical Oncology, the largest gathering of oncology professionals in the world, held in Chicago, USA, on June 2.
Check out the video of Dr. Heloisa Resende (Jardim Amália Research Center) talking about the study “A national survey of the current scenario and future perspectives of cancer research in Brazil” presented at the ASCO Annual Meeting 2023.
https://www.instagram.com/p/CtZ0oMcrwy
The main findings of the research clarify the following aspects:
- Demography of the participating doctors: Most of the doctors involved in the study work predominantly in capital cities and are linked exclusively to private health services. 57% of the interviewees work in the Southeast region and 77% in the capitals.
- Communication on Clinical Research: 1/3 of the doctors interviewed refer less than 1% of your patients to participate in clinical research
- The results of the study suggest a clear need for greater involvement of doctors in clinical research activities in Brazil. Strategies for patient education are identified as crucial to improve low recruitment rates and, consequently, increase the number of proposed trials in the country.
Here is the summary of the publication “Current scenario and future perspectives of clinical research in Brazil: a national survey”
Contexts: Epidemiological and clinical cancer research is essential for understanding tumor behavior and the development of new therapies in oncology. However, several countries, including Brazil, as well as many other regions of the world, have limited participation in clinical studies on cancer. Although 625,000 new cancer cases were registered in Brazil in 2022, only 2.2% of ongoing cancer clinical trials are available in the country. We conducted an online survey to describe the involvement of doctors with clinical research and to identify the main barriers that prevent the participation and conduct of clinical studies on cancer in the country.
Methods: An anonymous online survey with 23 objective questions was sent by e-mail to Brazilian members of the Latin American Cooperative Oncology Group and the Brazilian Society of Clinical Oncology. The first 13 questions addressed demographic information, medical education, and previous participation in research. In the second part, the main barriers to engagement and participation in clinical trials in Brazil were discussed. Continuous variables were measured by median and amplitude. The analyses were performed using the SAS statistical software (version 9.4; SAS Institute, Inc. Cary, NC).
Results: 109 doctors answered the survey. Most of the participants were oncologists (N = 98, 89.9%), resided in capitals (N = 84, 77.1%), came from the Southeastern region of Brazil (N = 63, 57.8%) and worked in institutions that provided exclusively private care (N = 59, 54.1%). Of the 109 interviewees, 83 (76.1%) reported working in research centers (as researchers or sub-researchers). Surprisingly, 31.2% of doctors recognized that they invite less than 1% of their patients to participate in clinical trials, although 98 (89.9%) consider patient participation in clinical trials to be extremely relevant. The main barriers to conducting research in the country were the low number of available trials (48.2%) and the lack of qualified human resources to equip research sites (22.9%). Other barriers reported were the lengthy regulatory approval process (42.2%), followed by patients' lack of knowledge of clinical research, resulting in low recruitment rates (24.1%). Of the 26 (23.8%) interviewees who do not work with research, 25 (96.1%) reported interest in getting involved, 31.8% had already tried to participate in research, and 62.4% reported limited knowledge of clinical trial procedures.
Conclusion: These results suggest a clear need for greater involvement of physicians in clinical research activities in Brazil. Patient education strategies should improve low recruitment rates and, secondarily, increase the number of trials proposed in the country.
Authors:
Heloisa Resende, Taiane Francieli Rebelatto, Gustavo Werutsky, Gustavo Cartaxo de Lima Gössling, Vinícius Aguiar, Guilherme Lopes, Biazi Assis, Lilian Martins Arruda, Carlos H. Barrios
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
During the official ceremony of the 2023 SBOC Congress, on November 17, the FIP-SBOC Award was awarded to notable projects that stood out significantly in the fight against cancer in Brazil. Among the winners, the Acceleration Project stood out as a promising initiative to accelerate the diagnosis and treatment of breast cancer in the country.
The Acceleration Project, led by Dr. José Bines and with the Cura Project Institute as co-director, received recognition and donation of R$ 150,000, for its Phase 2, from the SBOC Research Incentive Fund (FIP). This Fund aims to support the development of Brazilian oncology research studies and initiatives focusing on reducing disparities and seeking equitable access to treatments.
Acceleration Project
Starting in 2022, in its initial phase, the Acceleration Project brought together a fundamental partnership with the health team of the Zilda Arns Family Clinic, in Complexo do Alemão. During this period, educational activities were carried out on breast cancer, in addition to the establishment of the registry and the trajectory of patients resident in that location.
Phase 2 Acceleration Project
General Objective: To decrease breast cancer mortality by reducing its presentation in advanced advances (III and IV).
Main Objective: Reduce the time interval between suspicion and treatment of breast cancer, currently from 6 to 8 months, to less than 3 months.
In the Brazilian context, the breast lesion biopsy and the histopathological report represent bottlenecks in the timely diagnosis and initiation of breast cancer treatment. The innovative proposal of the Acceleration Project aims to reduce these obstacles, improving the outcomes of this disease that affects so many lives.
The continuity of the project focuses on training Primary Health Care professionals to perform ultrasound and biopsy of suspected palpable breast lesions at the point of care. The speed and accuracy in obtaining the histopathological report are key elements to accelerate the diagnosis, delaying the time until the start of treatment and, consequently, reducing mortality from breast cancer.
The project strategy is to shift the focus from the current emphasis on mammographic screening to the implementation of an early diagnosis, through an approach based on adequate resources. The objective is to prevent a significant number of deaths from breast cancer, changing the current reality.
SBOC Research Incentive Fund (FIP) Award
The recognition and award of the Acceleration Project, in the SBOC Research Incentive Fund (FIP), represent a significant milestone in the oncology research scene in Brazil and in the continuous effort to address breast cancer in Brazil, promoting innovation and advancement in the approach to this complex disease. The importance of the Cura Project Institute as co-director of this project stands out as an important initial supporter for the success and positive impact of this initiative.
The FIP-SBOC Award highlights not only the quality of the research, but also the direct impact on patients' lives, signaling a more hopeful future in the Brazilian oncology scene and the role of the Cura Project Institute with the project, highlights its commitment to promoting oncological research in Brazil, and the partnership between Dr. José Bines and the Cura Project Institute highlights the important collaboration between professionals and institutions, engaged in advances in cancer treatment.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
Highlights of the Poster presented by the Cura Project Institute and LACOG at the XXIV SBOC Congress
Last November 16, during the XXIV Congress of the Brazilian Society of Clinical Oncology (SBOC), a Dr. Heloisa Resende, oncologist and President of the Scientific Committee of the Cura Project Institute, presented an innovative poster developed in partnership between Cura and LACOG — Latin America Cooperative Oncology Group.
Titled “Improving access to clinical cancer research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023", the research brought to light important insights from 16 experts.
The paper, in poster format, corresponds to 4th Care Meeting, which took place in June 2023 in São Paulo. At the time, different representatives of the system of Clinical Research participants, such as CONEP, Anvisa, researchers, the pharmaceutical industry and NGO leaders, discussed how we can improve both scientific studies in the country and patient access.
According to the poster, clinical research is the cornerstone of improvements in cancer treatment. However, it has been conducted predominantly in high-income countries, with few clinical trials available in Brazil and other low- and middle-income countries.
The experts highlighted important achievements, including the reduction of time in regulatory processes involving Anvisa and CONEP. In addition, they emphasized the development of staff training programs, the maintenance of the National Oncology Care Program (PRONON), and the creation of qualified centers in the North and Northeast regions of Brazil. These advances not only strengthen clinical research infrastructure, but are also important for the decentralization of these activities, expanding access across the country.
However, the event's debaters also highlighted the need to make Brazil more competitive in the clinical cancer research scenario. This requires an optimization of ongoing policies. In this context, there was a consensus among the participants about the importance of strategies that allow patients to obtain clear information about participating in clinical trials and programs aimed at doctors with the objective of achieving greater involvement of them, such as more time allocated by hospitals so that they can dedicate themselves more to research activities.
Accessible information is vital to involve patients and promote their active participation in this process. Experts emphasized that active and consistent reporting of ongoing initiatives can help to spread continuous advances, increasing Brazilian participation in clinical cancer research.
Dra. Heloisa Resende, author of the research, tells us more about the important poster selected for presentation at the SBOC Congress 2023.
What was the motivation for the 4th Cura Meetings to become a survey?
- The need to record that Brazil is making progress in research, for example, providing opportunities for meetings between various sectors of clinical research, through this meeting in São Paulo. Recording these advances is necessary for professionals from other countries, also involved in research, to see us with greater confidence and see us as partners in future projects.
What was the main data obtained with the research?
- Understand that the obstacles to greater access to research go far beyond regulatory barriers, that is, they are indeed a problem, but there are several other aspects to be addressed, involving the behavior of doctors and patients, difficulty in obtaining information, and greater need for the engagement of the entire society.
What are the solutions and paths taken to the challenges observed with the research?
- The path involves the involvement of all of us. In principle, each sector plays its role, with the common objective of increasing access to research. So NGOs need to promote more awareness campaigns for society, medical researchers need to be more engaged, the government needs to optimize regulatory process times, and the pharmaceutical industry must provide more opportunities for new centers in Brazil.
In addition to the presentation of the poster, on November 18, the President of the Cura Project Institute, Fernanda Schwyter, participated in the “Clinical Research” Module at the congress.
During his participation, whose theme was “How organized society works to encourage Clinical Research in Brazil”, valuable experiences related to the organization of the Cura Project Institute were presented, further enriching the debate about the challenges and opportunities in clinical cancer research in Brazil.
Check out the publication in the eCancer Magazine: Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023 - ecan
The 2023 SBOC Congress took place from November 16 to 18, in person, in the city of Rio de Janeiro. The program was integrated into the 4th Brazilian Oncology Week, thus bringing together, in addition to clinical oncologists, oncologic surgeons, radiation oncologists, managers, researchers and many other professionals who form the country's large network of cancer care and care. The event is consolidated as a crucial space for the exchange of knowledge and strengthening the community involved in this vital field of medicine.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
The Cura Project Institute's campaign combats “fake news” about breast cancer on social media
With the pandemic, there was a great spread of false health news and, when it comes to cancer, incorrect information can be harmful to treatment and cause many health problems. But this is an older and very common conversation, where most cancer patients always receive “indications” of some miraculous cure for cancer: tea, a drink, and others, are offered by relatives and neighbors with the intention of helping, but they can end up getting in the way a lot.
With that in mind, the Cura Project Institute chose to follow a different line this Pink October, breast cancer awareness month, bringing a campaign to counter these myths in a direct and objective way: in big letters, false news is exposed and, in the following image, we see the message “The cure for cancer begins with research”.
“We, at the Cura Project Institute, believe in evidence-based medicine. What is that? It is the practice based on scientific studies and not on popular “guesses”, such as those detailed in the campaign”, explained Fernanda Schwyter, president of Cura.
According to Oncologist and Researcher, Dr. Liliam Arruda: “The search for a cure for cancer is based on research and the tireless commitment of the scientific community. However, the dissemination of disinformation, such as fake news, threatens to undermine the promotion of beneficial practices, underscoring the importance of basing our hopes and resources on truth and science.”
There are patients who are already aware of this issue and are committed to vetoing the dissemination of this type of information. This is the case of the health influencer, the publicist Paula Dultra, one of the pioneers to talk about breast cancer on social media. “I have been an oncology patient for 13 years and, in all that time, I've heard a lot of things! They have already told me to drink holy water, soursop tea, lemon water, and others. For me, who read, study, and create content, I already know that this doesn't work, but what about the patient who has no access to information? We have to think about that. That's why I use my site Mão na Mama and my social media profiles to help share secure information”, she said.
How to identify fake news?
The Cura Project Institute presents some careful guidelines before you pass on news that may not be true. Check it out below:
The most important thing is that when in doubt, you should not pass on the news and, if you can, consult a specialist.
Cura performs Live in Pink October, with the theme “Is there a cure for breast cancer?”
The Cura Project Institute is committed to the dissemination, information, and education about the importance of Clinical Research, and this month of Pink October would be no different. With an action that brings information to people, the institute intends to make people aware, through clear and objective language, of the best path to cure cancer. And to further expand this communication, the Institute will carry out through Instagram @Cura project a Live with the theme:”Is there a cure for breast cancer?”
Live will take place on October 19 at 8 pm, with Oncologists and Researchers Dr. Heloisa Resende and Dr. Lilian Arruda, to clarify and demystify myths and reinforce that curing cancer begins with research. At the invitation of Dr. Heloisa Resende, “the topic will be breast cancer, the most common cancer in women in Brazil. We will address the aspects related to the diagnosis and attitudes that we can all adopt towards a more favorable scenario, in which more lives are saved.”
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
Experts and patients met on the panel of the Cure Project Institute at the 10th All Together Against Cancer Congress and showed that the country needs to place greater value on clinical research.
“Just as all the drugs and vaccines we use today required research before being used, the cure for cancer also requires clinical studies to be found.” The phrase spoken by Fernanda Schwyter, President of the Cura Project Institute, during the panel “The cure of cancer begins with research” held last Thursday, the 28th, during the 10th All Together Against Cancer Congress, meets the institute's mission, which is to be a non-profit association that provides information, education and funding to support clinical research for the search for a cure against cancer.
With the presence of Dr. Heloisa Resende, Medical Oncologist and President of the Cura Scientific Committee; Sr. Claudiosvam Martins Alves de Sousa, Clinical Research Coordinator of the National Health Surveillance Agency — ANVISA; Dr. Ricardo Caponero, Clinical Oncologist at the Oswaldo Cruz German Hospital, Master in Molecular Oncology, Coordinator of the SBOC Palliative Care Committee, President of the FEMAMA Scientific Technical Council and Clinical Studies Co-Investigator; and Ana Cristina Angrisano, a clinical oncology research patient; the debates showed not only in theory, but also in practice with the testimony of an oncological patient undergoing treatment through clinical research, how important and capable of reversing a scenario they are, guaranteeing quality survival and control of this type of disease.
As mentioned by Dr. Ricardo Caponero, “studies must not only show that they work, but also that they are beneficial to patients and, for this, we need more research”.
In his explanation, Claudiosvam Martins, Research Coordinator at ANVISA, reinforced the thesis by saying that “there is still a huge space for investments in research in Brazil, mainly from domestic investments, from Brazilian companies”.
Impact of Clinical Research in Brazil
Dr. Heloisa Resende's presentation focused on Neosamba research, of which she is also one of the researchers through the Jardim Amália Research Center, in Volta Redonda (RJ). The study is currently in phase 3, recruiting 500 patients, coordinated by LACOG - Latin American Cooperative Oncology Group, bringing together 19 research centers in several Brazilian cities. The research seeks to confirm whether the new treatment sequence (taxanes and anthracyclines), with drugs already available in the SUS in women diagnosed with HER2-negative breast cancer, with neoadjuvant chemotherapy (before surgery), show an increase in disease-free survival and in the overall survival of women with this pathology.
The oncologist also showed that in breast cancers, 27% of cases are already found in advanced stages and asked the question: - “can I trust the treatment sequence I have with the disease at this stage?” , thus showing the relevance of rethinking the standard protocol used and its impact.
Headed by Dr. José Bines, principal investigator of the study, who presented phase 2 of this Neosamba research at ASCO in 2018, conducted at the National Cancer Institute - INCA, with 118 patients, showed great benefits in reversing the standard protocol and, with the actions of the Cura Project Institute, it is becoming possible to carry out this study, which will have a global impact.
In addition to presenting the benefits of the Neosamba research to the population, Dr. Heloisa showed important data from another study carried out by the Cura Project Institute, which will be published soon, and which need to be taken into account, such as:
Concluding the panel, Ana Cristina Angrisano, a metastatic breast cancer research patient and volunteer at the Cura Project Institute, told how she entered clinical research after the remission of her second cancer in 2015. “I started clinical studies in 2017, two years after the second diagnosis. At that time, the expectation was nil. When you receive such a diagnosis and are faced with a few months' survival option, obviously my choice was for life. And here I am, years later. I wish the surveys to be for everyone!”.
At the end, a video was presented of a campaign to publicize the Neosamba research, by actress Patrícia Pillar, carried out by the Cura Project Institute.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
Collaboration: Estrela Comunicação - Press Office
The research, carried out by the Brazilian Head and Neck Cancer Association, aims to map the reality of professionals who treat patients with this pathology at national level.
The Cura Project Institute supports Brazilian Head and Neck Cancer Association @ACBGBrasil in announcing the completion of the Extension Research, which aims to build an estimate of the national Head and Neck Cancer scenario.
This research will be carried out through the analysis of questionnaires applied with several professionals from the multidisciplinary team that treat these patients. Thus, for the first time in history, we will have an in-depth and real analysis of this cancer specialty and such data will contribute to the oversight of existing public policies and also to the construction of new ones, as well as serve as the basis for various projects aimed at the inclusion and rehabilitation of patients with head and neck cancer, as well as for the valuation of professionals working in the area.
Are you an oncology professional? There are 18 specialties, find yours and take part in the survey!
Click on your specialty to access the search. Alphabetical Links
1 — Administration
2 — Oral and Maxillofacial Surgery
4 — Dermatology
5 — Endocrinologist
6 — Nursing
7 — Pharmacy
8 — Physiotherapy
9 — Speech-Language Pathology and Audiology
10 — Nutrition
11 — Dentistry
12 — Oncology
13 — Otolaryngologist
14 — psychology
15 — psych
16 — Radioncologist
17 — Social Service
18 — Occupational Therapy
More information: redemaisvoz@acbgbrasil.org and (48) 9 9169-4019 — WhatsApp
Source: ACDG Brazil
Clinical research plays a fundamental role in the advancement of cancer treatment and, among the main sources of funding for these studies, are supporting companies. The Cura Project Institute highlights the importance of these companies for clinical oncology research, such as those developed by LACOG - Latin American Cooperative Oncology Group.
Cancer is one of the leading causes of morbidity and mortality worldwide, requiring continuous efforts to develop new therapies and treatments. According to Dr. Carlos Barrios, Oncologist and President of LACOG:
“Latin America has more than 600 million people and 1 million new cases of cancer each year. Clinical research is an opportunity for cancer patients, yet only 7.5% of cancer clinical trials are open in the region.”
LACOG, as a leading cooperative group in Latin America dedicated to clinical research in oncology, with an emphasis on the development of innovative therapies, is currently conducting 12 clinical studies and 24 epidemiological studies.
The NEOSAMBA study stands out, a study that evaluates the sequencing of neoadjuvant chemotherapy in patients with breast cancer. This study will include nearly 500 patients and will help define the best treatment strategy for patients with breast cancer. In this context, the Cura Project Institute, LACOG and GBECAM, are proud to thank the support of companies that play a crucial role in the advancement of clinical oncology research. They are: Arteris, Cristália, Crown Embalagens, Elo, Nutrien Agricultural Solutions, PRIO, Rede D`Or and XP.
About the Cura Project Institute
The Cura Project Institute, a non-profit entity, promotes scientific, educational and social activities to increase civil society's awareness of the benefits of clinical research and to raise funds to finance independent studies to combat cancer in Brazil. More information can be found on the official website of the Cura Project Institute and on its social networks Instagram, Facebook and LinkedIn
About LACOG
LACOG — The Latin American Cooperative Oncology Group — is a non-profit organization founded in 2009 by a group of Latin American medical oncologists interested in developing clinical research. This is the first multinational cooperative group in Latin America dedicated to clinical and epidemiological cancer research. LACOG currently has more than 507 member researchers present at 200 institutions in 16 Latin American countries. The group develops observational studies to describe the diagnosis, treatment, and survival of cancer patients in various types of tumors, and also conducts clinical trials investigating new
biomarkers and new drugs.
About GBECAM
GBECAM is an independent, non-profit organization whose main objective is to develop, implement, and facilitate the conduct of multi-institutional clinical studies of scientific and ethical quality on breast cancer in Brazil, as well as to implement and assist educational programs for the clarification and prevention of breast cancer.
The 17th National Health Conference, organized by the Ministry of Health and the National Health Council, which took place from June 2 to 5 in Brasilia, discussed approximately 2,000 proposals and guidelines that will subsidize public health policies over the next four years.
The event brought together more than 6 thousand representatives of civil society, entities, movements and social organizations and was preceded by several preparatory stages, thousands of municipal conferences and 99 free thematic conferences, in addition to conferences held in all states and the Federal District. In these stages, 249 guidelines and 1214 proposals were approved, which were systematized in the Consolidated National Report and discussed in the working groups during the 17th National Health Conference.
The approved proposals and guidelines were submitted at the time of the Deliberative Plenary, which was held on July 5th and aimed at debating, approving, or rejecting proposals from the Report and the national and international motions. Finally, the result will be indicated in the Final Report, which in turn will support the formulation of guidelines for the Multiannual Health Plan (2024-2027) and for the State and Federal District Health Plan (2024-2027), and will guide the SUS in the coming years.
Within this context, the Cura Project Institute held a Free National Conference on April 31 and was included in the consolidated document with the theme: “What you should know about research and cancer: challenges and opportunities”. Through the delegates elected at this conference, Luciana Papaleo Peixoto and Fernanda Schwyter, Cura participated in the 17th National Health Conference and was guided in its proposals by the following Directive:
“To promote research to prevent and combat cancer in Brazil based on education and awareness among the population, academics and health professionals based on the importance of clinical research, and the engagement of government agencies in the discussion about the need for more agile clinical trial approval processes and incentives that promote and attract studies in Brazilian institutions, providing relevant data in the field of public health and guaranteeing access to innovative treatments for cancer patients in public networks and private.”
The proposals presented by Cura have been approved and will be officially announced on the channels of the Ministry of Health, and they fulfill the role of planting a seed to have a stable environment for independent and academic clinical oncological research, within the barriers raised and debated by Cura, which are intended to impact the training of doctors and health professionals, fundraising, decentralization of research centers and motivation of the pharmaceutical industry to bring more studies to Brazil.
According to Fernanda Schwyter, President of the Cura Project Institute and delegate to the 17th CNS:
“These were days of hard work, of much discussion and mobilization, but of great achievement. Life is much better when we have a purpose and it is more enriching when we are engaged by society for the same purpose, and we completed the 17th National Health Conference with success and approval of proposals in oncology. So, congratulations to all of us who were able to complete another stage of the journey in the fight against cancer, because research saves lives”.
Cura supports the TJCC motion
Also during the 17th CNS, the Cura Project Institute supported the motion registered by the TJCC - All Together Against Cancer, which requests the updating of the care models for people with cancer in the SUS. With the special support of the member organizations of the TJCC: Abrale, Oncoguia, ACBG, FEMAMA, Cura and SBOC, it was possible to collect more than 400 signatures in support of the cause.
Source: text prepared based on information from the National Health Council
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org
The event, which brought together important names in the health sector at the debate table, discussed the topic that proposed expanding the population's access to Clinical Research and reinforced the urgency of joining efforts to facilitate information for cancer patients.
The Cura Project Institute successfully held the 4th Cura Meetings, on June 16, in São Paulo. The event, which took place in a hybrid way, had as its theme: “Expanding the population's access to Clinical Research” and brought together representatives from various health sectors.
LACOG Photos/Cura Project Institute
The central objective of the 4th Cura Meetings was to promote a productive discussion about patients' access to clinical research in Brazil, seeking ways to expand this dissemination and reduce existing bottlenecks for conducting research in the country. The event provided a space for participants to share their evidence and suggestions for the obstacles imposed on the process and access to research.
The event was attended by highly qualified speakers, including Dr. Nelson Teich, Oncologist and Master in Health Economics; Dr. André Gomes, Head of Clinical Operation Bristol Myers Squibb and Dr. Andreia Melo, Head of Clinical Research at the National Cancer Institute - INCA. Each of the speakers brought valuable perspectives about the scenario.
During the event, the speakers addressed fundamental issues, such as the barriers that hinder the population's access to clinical research, the importance of promoting inclusion in studies, and strategies to involve and engage doctors and patients. The lectures collected important data from the research scene in Brazil, as well as were marked by questions about how to overcome existing challenges.
According to Dr. Nelson Teich, who addressed the impact of clinical research on the evolution of health systems:
“Research must be part of a country's politics, especially public policies, and for me research is a source of information. Information is essential for you to understand the system, make a diagnosis, define priorities, define actions, and make choices. Research is much more than you bringing an innovation”.
A panel discussion with renowned names from the health sector provided the 4th Cura Meetings with a valuable opportunity to exchange knowledge. This discussion involved topics such as public policies, government incentives, and the importance of collaboration between sectors to strengthen access to clinical research.
Important names such as the Coordinator of the National Research Ethics Committee — CONEP, Lais Bonilha and the Clinical Research Coordinator of the National Health Surveillance Agency — ANVISA, Claudiosvam Martins Alves de Sousa participated in the debate at the 4th Cura Meetings, which also brought representatives from institutions such as the Chair of the Latin American Cooperative Oncology — LACOG, Dr. Gustavo Werutsky, the CEO and Executive Manager of the Brazilian Association of Representative Clinical Research Organizations - ABRACRO, Paulo Fernandes and Fernando Francisco and the Executive Director of the Brazilian Society of Clinical Oncology — SBOC.
The pharmaceutical area was also represented by the Associate Director of Astrazeneca — R&D Department, Dr. Roberto Jun Arai and NGOs, through the Executive Director of ABRALE/TJCC, Fábio Fedozzi.
The medical evidence from the debate at the 4th Cura Meetings came from the Oncologists and Members of the Cura Scientific Committee, Dr. Heloisa Resende and Dr. José Márcio Figueiredo, and from the Oncologist of the Hospital Sírio Libanês, Dr. Rodrigo Munhoz. To complete the panel, she was with the Cura Project Institute, the Master and Doctor in International Law — Lawyer and Researcher, Dr. Analuza Bolivar Dellari.
At the end of the 4th Cura Meetings, the participants concluded that it is essential to create a favorable environment for patients to have wider access to clinical research. To this end, it is necessary to promote public policies that encourage participation, increase awareness of the importance, and establish solid partnerships between the different health sectors.
The event takes place in the calendar of the Cura Project Institute, as an important moment in Clinical Research, becoming, with each edition, more inspiring and enriching, reinforcing the institution's commitment to playing a fundamental role in supporting information, education and other barriers imposed by the population's difficulty in accessing clinical research, such as: regulatory aspects, encouragement and training of doctors and health professionals, infrastructure and decentralization of Research Centers, investments in pharmaceutical laboratories and resources for the funding of independent research.
The 4th Cura Meetings, which was supported by the Latin American Cooperative Oncology Group (LACOG), the ETHICS Institute - Research and Teaching and PRIO, was attended by about 40 people in person, including participants and guests, with an audience of approximately 60 people who followed the event online and already generated more than 400 views for the recording of the meeting on YouTube. In order to expand knowledge on the subject, the recording of the 4th Cura Meetings is available on the YouTube channel of the Cura Project Institute. To access it, check out the recording below.
https://www.youtube.com/watch?v=39D2v-h-waI&t=9s
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org
The “Lacog 1018” Study, which was developed with the objective of evaluating the benefit of combining two medications, in women with advanced, polytreated ovarian cancer who expressed hormone receptors, had the oncologist of the Hospital Fêmina and the Oncology Research Center of the HSL-PUCRS, Dr. Fernanda Bronzon Damian, as principal investigator
The Renata Thormann Prociannoy Prize 2023, an initiative of the Cura Project Institute that encourages clinical research in Brazil, recognizes the “Lacog 1018” research, the study that was developed with the objective of evaluating the benefit of the combination of letrozole + palbociclbe in women with advanced ovarian cancer who were polytreated and who expressed hormone receptors as the big winner of the year.
The research was conducted with women who had already undergone 2 different chemotherapy treatments, but their needs were not yet met. With the research carried out by Dr. Fernanda, an inhibitor was proposed to treat the cases.
The research included the oncologist at Hospital Fêmina and the Oncology Research Center at HSL-PUCRS, Dr. Fernanda Bronzon Damian as principal investigator and co-authors: Andreia Cristina De Melo, Graziela Zibetti Dal Molin, Angelica Nogueira Rodrigues, Aknar Freire de Carvalho Calabrich, Gustavo Werutsky, Elias Abdo Filho, Taiane Francieli Rebelatto, Rafaela Gomes de Jesus and Mirela Foresti Jimenez.
The Scientific Committee for the award was composed of renowned oncologists, such as (in alphabetical order): Dr. Abna Vieira Dr. Max Mano, Dr. Cristiano de Pádua Souza, Dr. Eduardo Romero, Dr. Fernando Moura, Dr. Guilherme Harada, Dr. João Victor Alessi, Dr. Mariana Scarantini and Dr. Pedro Neffá.
According to Fernanda Schwyter, founder and president of the Cura Project Institute: “It is a great pleasure to stimulate the development of scientific knowledge in the country, collaborate with the improvement of treatment worldwide and improve the outcome of patients' quality of life”.
The 5th Renata Thormann Procianoy Prize 2023 was announced last Friday, June 16, during the Best Of ASCO Scientific Congress in São Paulo, by the president of the Cura Project Institute, Fernanda Schwyter, and presented by the president of the Scientific Committee, Dr. Max Mano, to the representative of Dr. Fernanda Bronzon Damian, Dr. Andreia Melo, co-author of the Lacog 1018 Study.
About the Renata Thormann Procianoy Award
Inspired by the story of the psychiatrist Nora Thormann, who had the help of her daughter Renata Thormann Procianoy in the search for research that would help diagnose and cure her health problem, which, after two years, resulted in the inclusion of Nora's case in a clinical study coordinated by the Peruvian Dr. Roberto Miranda at the MD Anderson hospital of the University of Texas (USA), the Prize is a recognition of the research that identified and treated Nora. The name is a
A tribute to Renata who, unfortunately, months later suffered a car accident and died, celebrating her tenth birthday this year. Check out Nora's testimony:
https://www.youtube.com/watch?v=ohLeWAOaBkg
About the Cura Project Institute
The Cura Project Institute, a non-profit entity, promotes social, scientific and educational activities to increase civil society's awareness of the benefits of clinical research and to raise funds to finance academic studies to combat cancer in Brazil.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
With the objective of motivating the scientific community to continue with its excellent investigations and to renew its impetus to help others, the prize awarded by the Cura Project Institute has already recognized renowned Brazilian professionals in its previous editions
The 5th Renata Thormann Procianoy Award, announced during the Best of ASCO (American Society of Clinical Oncology) 2023, will take place in São Paulo on June 16, the event, more than providing due recognition, seeks to motivate the scientific community to continue with its excellent investigations and renew its impetus to help the next and future generations, since it works in research in Brazil
can be challenging and draining due to lack of incentives.
In a ceremony that takes place annually as part of the main program of the Best of ASCO, — organized by LACOG (Latin American Cooperative Oncology Group) and Ethics — Research and Teaching, the Cura Project Institute has been awarding the award since 2019 that selects the best Brazilian work submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO).
As explained by the President of the Cura Project Institute, Fernanda Schwyter, the Renata Thormann Procianoy Prize is evaluated by a scientific committee made up of research doctors associated with LACOG.
Throughout its editions, the Renata Thormann Procianoy Prize has honored important and recognized Brazilian professionals, such as:
The award ceremony for the 5th Renata Thormann Procianoy Prize will be held at an event for guests in São Paulo and the dissemination may be followed by the Social Networks of the Cura Project Institute.
About the Renata Thormann Procianoy Award
Inspired by the story of the psychiatrist and researcher Nora Thormann Porcianoy, who had the help of her daughter Renata Thormann Procianoy in the search for research that would help diagnose and cure her health problem, which, after two years, resulted in the inclusion of Nora's case in a clinical study coordinated by the Brazilian Dr. Roberto Miranda at the MD Anderson hospital, the University of Texas (USA), the Prize is a recognition of the research that identified and treated Nora. The name is a tribute to Renata who, unfortunately, months later suffered a car accident and died, celebrating her tenth birthday this year. Check out Nora Thormann Procianoy's testimony:
https://youtu.be/ohLeWAOaBkg
About the Cura Project Institute
The Cura Project Institute, a non-profit entity, promotes social, scientific and educational activities to increase civil society's awareness of the benefits of clinical research and to raise funds to finance academic studies to combat cancer in Brazil.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
With 704,000 new cases of cancer expected per year in Brazil, the Cura Meetings event created by the Cura Project Institute reinforces the need to make society aware of the benefits of clinical research
The Cura Project Institute is holding the fourth edition of Cura Meetings, a meeting that aims to continue an important debate with representatives from different health sectors and to outline strategies to expand patients' access to research in Brazil. With the theme “Expanding the population's access to Clinical Research”, the event, online and free, is supported by the Latin American Cooperative Oncology Group (LACOG) and the ETHICS Institute - Research and Teaching.
The 4th Cura Meetings will take place on June 16, from 14:00 to 17:00 in São Paulo and will have a face-to-face format for guests and will be transmitted online, in order to expand the knowledge and dissemination of this very important topic. To have access to the broadcast, the public must register online and free of charge, Through the link and fill out the form. After that, registrants will receive the information to follow the event, wherever they are.
Cura Meetings is already part of the Cura Project Institute's calendar of actions, and has already brought to its discussion table multiple relevant actors involved in the scenario, such as the medical community, researchers, patient associations, the pharmaceutical industry, public authorities (Ministry of Health), the medical community, representatives of clinical research centers and CROs.
According to Fernanda Schwyter, President of the Cura Project Institute: “Cura Meetings is part of the actions to mobilize directly or indirectly to support the cause that the Cura Project Institute works on a daily basis. The expected result is society's commitment to funding studies
clinicals/academics promoting the best treatment of patients, especially cancer”.
With the presence of approximately forty authorities, doctors and members of civil society, the 4th Cura Meetings announces its preliminary schedule (subject to change). Check it out:
4TH CURA MEETINGS SCHEDULE - June 16, 2023:
14 at 14:15 - Overture
14:15 to 14:30 - 1st Conference: Health in Brazil and the World and the impact of
Clinical Research in the evolution of health systems - Dr. Nelson Teich - Doctor
Oncologist and Master in Health Economics
14:30 to 14:45 - 2nd Conference: Pharmaceutical Industry: Brazil in the context
worldwide - André Gomes - Head of Clinical Operation Bristol
14:45 to 15:00 - 3rd Conference: The challenges of academic clinical research in
Brazil - Dr. Andreia Melo - Head of Clinical Research at INCA
15:00 to 15:15 - halftime
15:15 to 16:45 — Debate
- Confirmed debaters:
16:45 to 17:00 - Final Thoughts and Closing
LEARN MORE AND SIGN UP FOR FREE
About Oncology Clinical Research
According to the 2023 Estimate on the Incidence of Cancer in Brazil released by the National Cancer Institute (INCA) of the Ministry of Health, the expectation is that there will be 704,000 new cases of cancer in Brazil per year from 2023 to 2025.
Under this scenario, scientific research is not only necessary but urgent, but to get an idea, only 2.3% of global studies are carried out in Brazil, and the average time for approval of clinical studies in the country is 215 days, much higher than countries such as Argentina (113 days), Mexico (86 days) and the United States (only 32 days). Barriers are also found for the institution
of these studies in Brazil, especially with regard to bureaucratic restrictions, multiple instances of government approval, unpredictability of the study approval schedule, restricted funding sources, lack of public interest and patient awareness.
Thus, in order for new drugs and improved protocols for cancer diagnostics, tests, and treatment to be available on the market to the population, several steps are necessary to obtain registrations for these products or procedures. This registration is only possible after the various phases of proving the efficacy and safety of the drug or procedure. This evidence is found in research trials, from basic research to clinical research, involving human beings.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
May 31 is World No Tobacco Day and oncologist Dr. Suellen Nastri Castro speaks about the topic at the request of the Cura Project Institute
According to the WHO (World Health Organization), smoking is the leading preventable cause of illness and early death in the world, and is related to several serious diseases such as cancer, chronic obstructive pulmonary disease (pulmonary emphysema and chronic bronchitis), coronary artery disease (angina and heart attack), and stroke (also known as “stroke”). In addition, the use of tobacco is also related to conditions such as infertility and sexual impotence.
It is estimated that smoking is associated with one third of all diagnosed cancers. Globally, there are more than 8 million deaths a year related to tobacco, 7 million from active use and 1.2 million from passive exposure.
Brazil is considered an example, a reference, as one of the countries that smokes the least, due to the establishment of federal anti-smoking laws. As a result, these laws allowed for a significant reduction in smoking in the country.
According to Dr. Suellen Nastri Castro, oncologist, “quitting smoking promotes several health benefits for individuals, including those who already have complications associated with smoking. The cessation of smoking, at any age, allows a significant increase in a person's life expectancy, in addition to, of course, improving the quality of life”.
The specialist also reinforces the importance of the existence of smoking cessation programs in several hospitals/institutions across Brazil, and that they have several professionals who assist the individual in this process, offering follow-up, drug treatments and psychotherapy. “It is highly recommended to carry out periodic examinations for the early detection of serious diseases related to cigarettes, such as low-dose radiation tomography annually in a population at risk for lung cancer, such as people who are smokers, or former smokers, aged 50-80 years“, said the doctor.
For more information, talk to your doctor. If you can't quit smoking on your own, ask for help!
Collaboration:
Dr. Suellen Nastri Castro (CRM-SP 151.417) - Clinical Oncologist at Hospital BP — The Benedicência Portuguesa de São Paulo. Author of the book Overcoming Lung Cancer and Pleural Mesothelioma from the Overcoming Cancer Institute. Graduated in clinical oncology from the Brazilian Institute for Cancer Control in São Paulo (now São Camilo Oncology)
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Action #TheMagalWay will benefit the Cura Project in a donation campaign
A campaign #TheMagalWay - Cycling to support cancer research, emerged in the life of Brazilian Marcos Magalhães, who lives in the United States, as a way to explore his passion for bicycle competitions to inspire people to practice physical activities and raise funds for a good cause: cancer research.
In this year's season, Marcos Magalhães will participate in several cycling events, the most important of which is a journey through the Patagonian Pampas, traveling across lakes and mountains along Chile's iconic Carretera Austral and Pacific fjords. This will take place in November of this year, in “Blue November”, which is a month dedicated to raising awareness about men's health problems, focusing on prostate cancer.
And for that journey, Marcos chose the Cura Project Institute to benefit from the donations collected in the action, which, in the words of the cyclist himself: “I set an ambitious goal because we know that, with the support of people like you, we can achieve it. Please be sure to make your donation and follow my journey at @themagalway” — explains the athlete.
Learn more about the #TheMagalWay journey, following the cyclist Marcos Magalhães on his Social Networks @themagalway and, to participate with a donation, simply log in and access the link: https://projetocura.org/c/themagalway/
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The Cura Talks event brought together patients, families, companies, NGOs and health professionals and a Free Conference of the National Health Council was held.
On March 31, Cura Talks took place, with the theme “What You Should Know About Research and Cancer: Challenges and Opportunities”. The event, presented by ONE - Ocean Network Express, with the support of LACOG - Latin American Cooperative Oncology Group and about 20 other health institutions as institutional support, took place at the Hotel Intercontinental, in São Paulo - SP.
With more than 100 people present and more than 80 watching the live broadcast, the public can attend lectures and debates with Dr. William William (oncologist), Caio Viana (psychologist), Leonardo Husz (nurse specializing in oncology) and Dr. Julio Antônio Pereira (oncologist), as well as testimonials from the patient Ana Cristina Angrisano and others present.
Cura Talks also included a Free Conference of the National Health Council, where a debate, proposal and the election of two Delegates, Fernanda Schwyter and Luciana Peixoto, who will participate in the 17th National Health Conference, with the objective of submitting proposals to increase access to research for cancer patients.
In addition, the Cura Project Institute paid a brief tribute to the people and companies that believe in and support our project and struggle. We register here our thanks to ONE, Alta Saúde, ICB, Clínica Prognostica and Silvana Nunes - donor and representative of individual donors.
Check out some images from our event!
To see more photos, click here.
Image credits: Jefferson Corrêa/RB Films
Those who were unable to attend the live event can check out the saved broadcast on our channel at youtube
https://www.youtube.com/watch?v=8bHPtgZuwIQ&t=15s
Cura Talks is another of the Cura Project Institute's proprietary events of many yet to come!
Be part of our community and take part in our actions!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The Cura Project Institute joins the fight to mobilize Civil and Medical Institutions and Societies against the #Veto59 of PRONON and PRONAS/PCD.
The Cura Project Institute joined hundreds of Civil Society Institutions and Medical Societies to create a mobilization to obtain, together with the Federal Government, the return of the PRONAS/PCD (National Health Care Support Program for the Disabled) and PRONON (National Oncology Care Support Program) Programs.
These programs brought significant investments in scientific research, training, and public access to innovative treatments that promoted advances in cancer care and rehabilitation for thousands of Brazilians.
This is the moment for everyone to come together to get parliamentarians, from the Senate and the Chamber, to overturn the veto of Bill 5,307/2020, authored by Senator Mara Gabrilli, which extends the possibility for private companies to donate funds to projects approved by the Ministry of Health in the areas of Oncology and Physical Rehabilitation, by deducting 1% from the Income Tax return, made by Real Profit.
Medicine has come a long way in recent years, but this is only possible with resources and, therefore, PRONON And the PRONAS/PCD They are essential. These resources are invested in actions for the SUS and in the care of the population that uses the system where, through various activities such as scientific research, purchase of equipment, training, among others, institutions can provide effective assistance to cancer patients and people with disabilities. The time has come to demand political participation on behalf of people in need.
Take part in this mobilization, nonpartisan and share!
Let's fight for the right to have inclusive and high-quality medicine!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The Cura Talks event takes place in São Paulo and will enlighten patients, NGOs and companies about Research and Cancer
On March 31, 2023, the Cura Project Institute will hold another proprietary event, the 1st Cura Talks. Under the theme “What You Should Know About Research and Cancer: Challenges and Opportunities”, O Cura Talks aims to promote knowledge and awareness about research that seeks a cure for cancer, as well as to engage patients, NGOs and companies to the cause.
Since its founding, Instituto Proyecto Cura has been holding social and corporate events to promote society's awareness, funding, and engagement in favor of research that seeks a cure for cancer.
Cura Talks, which has the support of LACOG - Latin American Cooperative Oncology Group -, will feature lectures by medical oncologists and other renowned specialized professionals in the field of research, who will share relevant and important information on the topic. For the opening of the event, which will address “Magnitude of cancer patient care”, we will have the important name of Dr. William William, a leading physician in clinical oncology, member of the Scientific Committee of the Cura Project Institute, Associate Adjunct Professor at the MD Anderson Cancer Center, Coordinator of the Thoracic Tumors Committee of the SBOC (Brazilian Society of Clinical Oncology) and President of the Head and Neck Cancer chapter of LACOG.
The first edition of Cura Talks will take place in a hybrid form, with a live broadcast and, subsequently, the conferences will be available on the digital platforms of the Cura Project Institute, so that this very important issue can be broadened and informed to more patients, support networks, other doctors and various supporters of the cause.
Check out the schedule:
13:30 — Welcome to the in-person audience
14H — Opening and Start of the online broadcast
14:15 TO 14:35 - Magnitude of cancer patient care - Doctor Oncologist Dr. William William
14:35 TO 14:55 - Myths and Truths about participating in Clinical Research — Psychologist Caio Vianna
14:55 TO 15:30 — Papo Cura: Ask your questions
15:30 TO 15:45 - halftime
15:45 TO 16:45 - Papo Cura: Understanding Everyday Clinical Research - Debaters: Nurse Specialized in Oncology Leonardo Husz and Clinical Oncologist Dr. Julio Antônio Pereira
16:45 to 17:30 — Cura Recognition — Delivery of Certificates and Closing
Learn more about the Cura Project Institute
The Cura Project Institute is a non-profit institution, based in Brazil (São Paulo) and unique in
Latin America, whose objective is to finance academic research in the area of oncology.
According to the World Health Organization, already in the next decade, two out of every three people will be
diagnosed with cancer, which is expected to become a true epidemic. The consolidation of the activity
Research is one of the solutions to meet the needs of the population, particularly those who
depends on the public health system, reducing discrepancies and facilitating access to the best
treatments for everyone.
Service:
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The BIG - Breast International Group is the largest global network of academic research groups.
The history of the Institute Cura and BIG Project began in 2012 at an international scientific event, the Inter-American Breast Cancer Conference, in Cancun, where our president Fernanda Schwyter Did you meet the teacher Dr. Martine Piccart - president and co-founder of Breast International Group. It was at this meeting that the Cura Project Institute began to be designed, with the mission of carrying the message of the importance of international collaborative research to Latin America.
Some years later, in 2014, in Porto Alegre, when Cura was still being conceived, our president planned and coordinated a meeting between Dr. Piccart and Latin American researchers, the “BIG Latin American Groups Retreat”, an event that was held in Porto Alegre with the support of LACOG.
After that event, in the same year, Fernanda was invited to spend a week with the BIG team learning about Fundraising and awareness campaigns for research. This knowledge was essential for the development of Cura and is now strengthened with mutual institutional support!
To celebrate this moment, we interviewed the institution's team and brought their vision about the Cura Project Institute and the importance of the culture of philanthropy and of scientific research.
What is the importance of research for improving cancer treatment?
Research is the only way to improve cancer treatments — make them more effective, reduce their side effects, and adapt them to the individual needs of patients. This is because research is the only way to understand the biology of any specific form of cancer in order to determine the best possible way to treat it. Without research, we will not be able to cure cancer or end the great suffering and death of millions of people every year.
What is the biggest challenge for researchers to carry out research? Get funding to carry out your research. But to do that, the general public and potential donors need to understand why research is important and how research can improve and save lives.
Why is it important to engage in campaigns?
They serve to inform the general public and all those who can potentially play a role in supporting research. Campaigns can explain the importance of research, dispel myths about research, and show concretely how research leads to better treatments and cures for diseases such as cancer.
What are the direct and indirect benefits for patients?
Research leads to new treatments, which can extend patients' lives and improve quality of life; it also leads to cures. Indirectly, research reduces human suffering and, by improving people's health, it also reduces the burden on health systems.
What is the importance of the CURA Project Institute in this scenario?
CURA plays a critical role in bringing people together to help increase cancer awareness in Latin America and explain the essential role played by global research and collaboration in tackling cancer. CURA also collects essential resources for research. Without this, research cannot advance, progress cannot be made, and lives will continue to be lost because of cancer.
What is the importance of the CURA Project Institute for BIG's achievements?
CURA contributes to the success and strength of BIG member groups based in Latin America, in particular LACOG (Latin American Cooperative Oncology Group). In this way, LACOG can continue to develop important studies on breast cancer to be conducted in Brazil, Latin America and other regions, and its researchers can share their knowledge and experiences in Latin America. This helps to make global BIG studies more relevant to patients wherever they are in the world.
How can we count on BIG in developing a culture of philanthropy for research in Latin America?
The vision of the Breast International Group (BIG) is to find cures for breast cancer, facilitating collaboration between its academic research groups located around the world. Its primary purpose is to develop and execute breast cancer clinical trials and research programs that answer important questions for patients. To help raise funds for BIG studies with few resources, BIG established its own philanthropic team called “BIG against breast cancer”. This team and the leadership at BIG's headquarters in Brussels, Belgium, are available to advise LACOG and the CURA Project on their philanthropic initiatives.
About BIG
Breast International Group is a non-profit organization that represents the largest global network of academic research groups dedicated to finding better treatments and cures for breast cancer, with headquarters in Brussels, Belgium.
This long-standing interaction has now been transformed into an official partnership where BIG supports Cura institutionally!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Institutions Cura and Abrale carried out actions in partnership to promote the promotion of Leukemia Awareness Month.
O Cura Project Institute and ABRALE - Brazilian Lymphoma and Leukemia Association came together once again in favor of a noble cause: raising awareness about Leukemia, in celebration of Orange February - a month that marks various initiatives on the subject. This partnership is part of the “Research Save Lives Movement” campaign, initiated by Cura, to inform and educate about the importance of clinical research in the fight against cancer.
Since the beginning of February, the Cura Project Institute has engaged in digital actions together with the NGO. First, we support the campaign #VaiDeLenço, which was linked to World Cancer Day, which was February 4th.
In addition, throughout the month, there were also:
About Leukemia
Leukemia is a malignant disease of white blood cells, generally of unknown origin, characterized by the replacement of normal blood cells, which give rise to the accumulation of diseased cells in the bone marrow.
It is very important that early diagnosis to increase the chances of curing this type of cancer, which may present symptoms such as: anemia resulting from reduced red blood cells (fatigue; shortness of breath; palpitation; headache); reduction of white blood cells (low immunity, which leaves the body more prone to infections); decreased platelets (bleeding generally in the nose or gums; purple spots - ecchymoses and purple spots on the skin).
Exposure to pesticides, solvents, diesel, dust, hepatitis B and C virus infection: leukemias
Early diagnosis is very important to increase the chances of curing this cancer, which may present symptoms such as anemia resulting from reduced red blood cells (fatigue; shortness of breath; palpitation; headache); reduction of white blood cells (low immunity, which leaves the body more prone to infections); decreased platelets (bleeding generally in the nose or gums; purple spots - ecchymoses and purple spots (petechiae) on the skin).
Also, how are these Diseases don't choose age, it is important to always be alert, especially in children and the elderly.
About ABRALE
A ABRALE (Brazilian Lymphoma and Leukemia Association) is a non-profit, national organization created in 2002 by patients and families with the mission of offering help and mobilizing partners so that all people with cancer and blood diseases have access to the best treatment.
The institution has a headquarters in São Paulo, with more than 60 employees who work in different areas, as well as a staff of 13 external representatives in the following cities: Belo Horizonte, Brasília, Campinas, Curitiba, Florianópolis, Fortaleza, Goiânia, Juiz de Fora, Recife, Ribeirão Preto, Rio de Janeiro, Salvador and São Paulo, and also has approximately 200 active volunteers, who help carry out actions for health and well-being. To learn more about ABRALE, visit the website And the Instagram.
We were very grateful for this additional support from ABRALE and for the opportunity for collaboration between NGOs. Always count on us!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
The Institute presents a retrospective of educational events and actions in favor of scientific research.
In another year of holding events, face-to-face lectures, live shows, awards and much more, Cura Project Institute Celebrate your 6 years of existence and promotes dialogues between the main actors of cancer care in Brazil.
In addition to educational posts on social networks for the dissemination of quality information about cancer and research, Cura continued with its Periodical lives that had been started in 2021. Foram 11 in total, including partners, patients, NGOs, doctors, and others.
There were several participations in face-to-face and online events, such as the lectures of PRio, Brazilian Breast Cancer Conference, from the Academy for Media and Patients with Information and Science (Gramado Breast Cancer), at the London Global Cancer Week and the LACOG Immuno-Oncology Symposium.
In June, the 4th edition of Renata Thormann Procianoy Award which, since 2019, recognizes the work of Brazilian researchers with cancer research. That year, the winner was Dr. Verônica Torres (ICESP). She was the principal investigator, with Dr. Gilberto Castro as co-author, of the “Prospective study evaluates the performance of the 2021 CKD-EPI equation without racial coefficient in adults with solid tumors”, on aspects related to the care of renal treatment in cancer patients. Before her, we had winners Dr. Luciana Landeiro (2021), Dr. Fernando Maluf (2020) and Dr. Thiago Bueno (2019).
The Cura Project Institute also celebrated its title, provided by the Ministry of Justice, as an OSCIP - Civil Society Organization of Public Interest. The purpose of this title is to:
📌 facilitate partnerships and agreements with all levels of government and public bodies;
📌 allow donations made by companies to be deducted from income taxes.
This was another important step that will help with the purpose of raising funds to finance research to combat various types of cancer.
A series of their own events also took place, such as:
Still in October, Cura Project Institute launched a very important campaign, the “Research Save Lives Movement”, which aims to help clarify the benefits and their nuances from the point of view of the cancer patient. To learn more click here and check out the video, with the patient's testimony I'm going to Fluminham.
https://youtu.be/K2g64R_ws7k
In addition to all initiatives, the Cura Project Institute's social networks are still available for wide dissemination of scientific studies that are recruiting patients. To learn more and submit research from your center for outreach, send an email to campanhas@projetocura.org
We wish 2023 to arrive full of partnerships and achievements, counting on the support of everyone who was with us in 2022! May we all take advantage and set as goals for next year: to understand more about research, to help, and to share correct information on the topic!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at campanhas@projetocura.org
The initiative is yet another source of information about the benefits of clinical research and its nuances from the point of view of the main beneficiary: the cancer patient.
It is through clinical research that medicine evolves. These studies are essential so that we can learn more about diseases, develop new drugs, vaccines, treatments, and tests. COVID-19 brought the world's population the spotlight on the importance and benefits of research to save millions of lives where, in an international effort and in record time, science, through doctors and researchers, brought the solution to the pandemic.
As with COVID 19, a cure for cancer is also in research, but for this, it is necessary to overcome many challenges, especially in Brazil, including: funding, awareness, regulation, and encouragement of scientific production.
And it was in view of these challenges that the Cura Project Institute devised the “#PesquisasSalvamVidas Movement” campaign. The objective is to generate engagement from all sectors of society that can act in favor of these researches that seek a cure for cancer, from regulation to the viability of clinical studies. The initiative will also provide social education and clarify the benefits of clinical research and its nuances from the point of view of the main beneficiary: the patient.
The campaign was launched in Pink October 2022, on the occasion of the Cura Meeting event, but the campaign still has no definite date for its completion, as it will gain strength with the engagement and support of various entities, groups and NGOs engaged in initiatives involving the fight against cancer.
The video that launched the “Research Saves Lives” Movement features the testimony of Iramara Fluminhan, a cancer patient who was diagnosed with metastatic breast cancer 8 years ago and is now only alive today thanks to research. Learn about Iramara's inspiring story in this video:
https://youtu.be/K2g64R_ws7k
About the Cura Project Institute
Founded in 2016, the Cura Project Institute is a non-profit institution, based in Brazil and unique in Latin America, whose objective is to finance academic research in the area of oncology. To learn more about Cura, click here
To learn more about the #PesquisasSalvamVidas Movement, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
In another year of actions, the Pink October events and actions held by the Cura Project Institute were a success.
The month dedicated to the fight against breast cancer had important events for the Institute
Cura Project, which held two events: the 3rd Cura Meetings and the 1st Immunotherapy Forum for Patients, which took place on October 7th and 8th in São Paulo.
Both events addressed essential issues in favor of Clinical Research in Brazil. As they took place in a hybrid way, they allowed the participation of a large audience, coming from different parts of Brazil.
Addressing the topic “Clinical Research as a Form of Social Inclusion - Expanding the
access to Clinical Research in Brazil”, to 3rd Edition of Cura Meetings It was attended by
renowned medical researchers, representatives of NGOs, patients, the Pharmaceutical Industry, in addition to
important participation of the Ministry of Health and Anvisa. The event, which took place on October 7, promoted an unusual discussion between these important decision-making fronts regarding Clinical Research.
CLICK HERE and check out the recording of the 3rd Cura Meetings event
Already 1st Immunotherapy Forum for Patients, which took place on October 8, provided many significant explanations about immunotherapy - one of the most current and innovative types of cancer treatments. This knowledge was presented in a simple and didactic manner, making it easier for the public to understand. This was a good opportunity for the audience, in person and online, to ask questions about the topic.
Renowned oncologists and researchers were part of the Forum, such as Dr. Gustavo Werutsky - president of LACOG (Latin American Cooperative Oncology Group), Dr. Heloisa Resende - president of the Scientific Committee of the Cura Project Institute, Dr. William William and Dr. Lilian Arruda - members of the Cure Committee and Dr. Jose Márcio Figueiredo - director of the Cancer Institute Brazil. These are all medical professionals who go hand in hand with the Cura Project.
CLICK HERE and check out the recording of the 1st Immunotherapy Forum event for
Patients
Along with the events, the Cura Project Institute also launched
warfare “Research Save Lives Movement”, who seeks to raise awareness about
importance of scientific research. To be aware and to be able to engage with the cause,
Follow our social networks @projetocura
Watch the exciting campaign launch video BY CLICKING HERE.
Still as part of the actions of Pink October, the Cura Project Institute was held on the 13th of
October, at Prio, in Rio de Janeiro, speaking to the company's employees about prevention and the importance of early diagnosis of breast cancer, through a lecture by Dr. Jose Bines, and also about how important clinical research is for cancer patients and for society, with the participation of the President of Cura, Fernanda Schwyter.
On October 24, the Cura Project Institute participated in an online chat with
employees of Arteris, through the collaboration of the oncologist Dr. Ricardo Caponero and from the President of Cura, Fernanda Schwyter.
On October 25, Fernanda Schwyter and the vice-president of the Cura Project Institute, Alcina Mara, participated in TurniCast, a podcast hosted by Leandro Caleguer and Vitor Dias, about the importance of scientific research in the fight against cancer.
https://youtu.be/4rNcNipNUQM
Our objectives in participating in live shows and lectures at various companies are those of to make society aware of the benefits of research to combat cancer and to engage them in actions to obtain resources to finance studies.
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Another event from the Cura Project Institute will take place on October 8.
The Cura Project Institute will hold, on October 08, at the WTC Sheraton, in São Paulo, the “Forum
of Immunotherapy for Patients”. The event aims to improve patient outcomes
oncological diseases in Brazil through the evolution of science and research. Cura hopes to educate and equip patients, family members, and patient association leaders, presenting the
opportunities to participate in clinical studies such as access to new treatments, such as
immunotherapy.
Over the past 10 years, a large investment has been made in oncology research in
search for new therapeutic options that improve patients' quality of life and increase
chances of cure and/or control of the disease. One of the main treatments that has shown promise
it's immunotherapy. It is a type of treatment, with a medication that boosts the person's immune system so that the body can fight cancer more effectively. The adverse event profile (side effects) is different from traditional chemotherapy and has been well tolerated by most patients.
Immunotherapy is being studied through clinical research in various types of cancer, such as breast, lung, stomach, bladder, kidney, colon and melanoma cancers. However, each type of cancer responds differently to immunotherapy, alone or combined with other treatments, such as chemotherapy. There is still a long way to go in the sphere of knowledge about immunotherapy, understanding, for example, which patients will benefit the most from this type of treatment, and for this reason, clinical research in oncology plays a fundamental role.
That is why we must continue to invest so much in the development of new clinical research with
immunotherapy, as well as empowering patient associations, activist patients and their families, which
It is immunotherapy, what is clinical research and how to participate in studies, demystifying stigmas and
clarifying doubts.
Given the relevance of the topic, it is necessary to unite efforts between the medical profession and public policies
adequate and good level of clarification from patients and patient support associations.
Considering this objective, the Cura Project Institute will hold the 1st Immunotherapy Forum for Patients with the theme “Clinical Research as a form of access to immunotherapy”. The forum will reach an audience of NGO leaders, patients and doctors and will be presented in a hybrid form, where the public can follow the Cura Social Networks, where the link will be available to follow the event online.
Check out the schedule:
11 a.m. to 11:15 a.m. - Aperture
MODULE 1
O 11:15 to 11:35 - Conference 1 (Dr. Heloisa Resende) - Was every treatment once a research?
What Are the Different Types of Cancer Treatments?
O 11:35 to 11:55 - Conference 2 (Dr. William William) - Immunotherapy Concept. What changes
with Immunotherapy? Advantages and disadvantages of treatment. For what types of cancer
Do we have immunotherapy?
O 12:00 to 12:20 - Conference 3 (Dr. Gustavo Werustsky) - Research as a way of accessing
patients to immunotherapy. How can we optimize this strategy? There are researches being
developed by LACOG and other Immunotherapy institutions in Brazil?
O 12:20 to 12:30 - Interval
MODULE 2
O 12:30 to 13:30 - Discussion/Questions (Dr. Heloisa Resende and Dr. Lilian Arruda) - What is the role
of NGOs with Clinical Research?
Making the patient aware of becoming a research patient.
How to approach patients to participate in clinical studies?
Or 13:30 to 14:00 - Closing
About the Cura Project Institute
The Cura Project Institute is a non-profit institution, based in Brazil and unique in
Latin America, whose objective is to finance academic research in the area of oncology.
According to the World Health Organization, already in the next decade, two out of every three people will be
diagnosed with cancer, which is expected to become a true epidemic. The consolidation of the activity
Research is one of the solutions to meet the needs of the population, particularly those who
depends on the public health system, reducing discrepancies and facilitating access to the best
treatments.
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Through the “Cura Meetings” meetings, the Cura Project Institute promotes knowledge and access to Clinical Research in Brazil
With the objective of expanding the knowledge and engagement of different sectors of civil society
to reduce the cancer incidence in Brazil, the Cura Project Institute launched a project that carries out
periodic meetings called “Cura Meetings”, which promote discussions between renowned doctors
of the area, on various topics and giving the public the opportunity to learn about the benefits and
challenges for carrying out research in the fight against cancer.
With two successful editions already held, Cura Meetings premiered in April this year
year. The first edition, held at the Best of San Antonio Breast Cancer Symposium, organized by GBECAM — LACOG, in São Paulo, held three meetings: Cura Meetings Donors, Cura Meetings
NGOs, focusing on the topic “Clinical Research and Social Inclusion”, and Cura Medical Meetings.
Already in its second edition, which took place in June of the same year, Cura Meetings had as its theme “The challenges of public policies aimed at regulating and encouraging oncological research in Brazil”, raising a discussion about an essential area for confronting cancer in our country. In this edition, which took place on the occasion of the Best Of Asco 2022 Annual Meeting in São Paulo, the meeting put aside common interests and the importance of joint efforts in social mobilization for the reactivation of the PRONON program — National Oncology Care Support Program, which had its regulations expired at the end of 2021.
The next Cura Meetings will take place on October 7th, from 14:00 to 17:30, at the WTC Sheraton São Paulo, in a hybrid form (in person and online), and will address the topic “Clinical Research as a Form of Social Inclusion - Expanding Access to Clinical Research in Brazil”, aimed at encouraging the development of new research and the need to encourage new public policies and technologies to promote the improvement of patient outcomes.
At the time, an important campaign will also be launched in favor of Clinical Research in Brazil. Headed by the Cura Project Institute, “Clinical Research Movement” It will aim to develop
together with other institutions, including patient NGOs, a movement that aims to raise awareness and
promote a discussion between regulatory bodies, such as the Ministry of Health, ANVISA (National Health Surveillance Agency) and CONEP ( National Research Ethics Commission) with
medical community, research, industry, and patient support associations.
Once again, the Cura Project Institute is leading the way in promoting education and carrying out effective actions to encourage support for clinical research as a way to combat cancer and save lives!
About the Cura Project Institute
The Cura Project Institute is a non-profit institution, created in 2016, with headquarters in Brazil and unique in Latin America, whose objective is to finance academic research in the area of oncology. Cura works both online, through the website and social networks, and offline, with the holding of scientific, social and artistic events, mobilizing civil society and companies.
According to the World Health Organization, already in the next decade, two out of every three people will be
diagnosed with cancer, which is expected to become a true epidemic. The consolidation of the activity
Research is one of the solutions to meet the needs of the population, particularly those who
depends on the public health system, reducing discrepancies and facilitating access to the best
treatments.
To learn more about the Cura Project projects, visit our Donation tab, follow our Social Networks @projetocura or contact us at eventos@projetocura.org
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
.jpg)
_20250718_163507_0000.png)
